|
Age in years, average ± SD
|
72 ± 12
|
|
Sex % (n)
|
|
Male
|
64% (58)
|
|
Female
|
36% (33)
|
|
Anticoagulation drug, % (n)
|
|
Enoxaparin only
|
66% (61)
|
|
Fondaparinux
|
12% (11)
|
|
UFH only
|
9% (8)
|
|
Bridging heparin + enoxaparin
|
6.5% (6)
|
|
Other LMWH or ULMWH
|
5.4% (5)
|
|
Coumadin only
|
1% (1)
|
|
Time to lesion onset, days, mean ± SD
|
7.0 ± 6.4
|
|
Location % (n)
|
|
Extremities only
|
67.9% (36)
|
|
Extremities +torso
|
26.4% (14)
|
|
Face, neck, head included
|
5.7% (3)
|
|
Management % (n)
|
|
Discontinued
|
57% (52)
|
|
Continued
|
23.1% (21)
|
|
Treatment changed or dose reduced
|
14.3% (13)
|
|
Unknown
|
5.5% (5)
|
|
Time to resolution, days, mean ± SD
|
13.0 ± 7.4
|
|
If continued any AC
|
13.9 ± 7.8
|
|
Discontinued AC
|
12.1 ± 7.9
|
